Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Still a Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares saw strong trading volume on Friday . 294,592 shares traded hands during trading, an increase of 116% from the previous session’s volume of 136,389 shares.The stock last traded at $16.44 and had previously closed at $16.09.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ALPMY shares. Smbc Nikko Sec. upgraded Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Astellas Pharma Stock Up 2.6%

The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09. The company has a 50 day moving average price of $14.67 and a 200 day moving average price of $12.66.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.15. Astellas Pharma had a return on equity of 23.62% and a net margin of 15.63%.The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.21 billion. On average, research analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).